Tifenazoxide (NN414) is a potent and orally active selective KATP channel opener targeting SUR1/Kir6.2; it exhibits antidiabetic effects by inhibiting glucose-stimulated insulin secretion both in vitro and in vivo, and improves glucose homeostasis; it reduces basal hyperglycemia, enhances glucose tolerance, lowers hyperinsulinemia during an oral glucose tolerance test (OGTT), and improves insulin secretory responsiveness ex vivo in male VDF Zucker (fa/fa) rats.